公开(公告)号：US11208690B2

公开(公告)日：2021-12-28

申请号：US16579652

申请日：2019-09-23

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Seth Sadis ,  Paul Williams

IPC: C12Q1/6886 ,  C12Q1/686

Abstract: Methods for predicting clinical outcome for a human subject diagnosed with squamous cell lung carcinoma using a panel of molecular markers that includes CDKN2A and CCND1. The markers are related to the subject's increased likelihood of a negative clinical outcome.

公开(公告)号：US10421994B2

公开(公告)日：2019-09-24

申请号：US15948908

申请日：2018-04-09

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Seth Sadis ,  Paul Williams

IPC: C12Q1/6886 ,  C12Q1/686

Abstract: Methods for predicting clinical outcome for a human subject diagnosed with squamous cell lung carcinoma using a panel of molecular markers that includes CDKN2A and CCND1. The markers are related to the subject's increased likelihood of a negative clinical outcome.

公开(公告)号：US20180298423A1

公开(公告)日：2018-10-18

申请号：US15948908

申请日：2018-04-09

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Seth SADIS ,  Paul Williams

IPC: C12Q1/686 ,  C12Q1/6886

CPC classification number: C12Q1/686 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Methods for predicting clinical outcome for a human subject diagnosed with squamous cell lung carcinoma using a panel of molecular markers that includes CDKN2A and CCND1. The markers are related to the subject's increased likelihood of a negative clinical outcome.

公开(公告)号：US12139753B2

公开(公告)日：2024-11-12

申请号：US16825238

申请日：2020-03-20

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Rajesh Gottimukkala ,  Amir Marcovitz ,  Jeoffrey Schageman ,  Varun Bagai ,  Jian Gu ,  James Veitch ,  Kelli Bramlett ,  Scott Myrand ,  Fiona Hyland ,  Seth Sadis ,  Paul Williams

IPC: C12Q1/68 ,  C12Q1/6851 ,  G06F17/18 ,  G16B25/10

Abstract: A method for detecting a gene fusion includes amplifying a nucleic acid sample in the presence of primer pool to produce a plurality of amplicons. The primer pool includes primers targeting a plurality of exon-exon junctions of a driver gene. The amplicons correspond to the exon-exon junctions. The amplicons are sequenced and aligned to a reference sequence. The number of reads corresponding to each amplicon is normalized to give a normalized read count. A baseline correction is applied to the normalized read counts for the amplicons to form corrected read counts. A binary segmentation score is calculated for each corrected read count. A predicted breakpoint for the gene fusion is determined based on the amplicon index corresponding to the maximum absolute binary segmentation score. Gene fusion events may be detected in a partner agnostic manner, i.e. without prior knowledge of the specific fusion partner genes or specific breakpoint information.

公开(公告)号：US20250084470A1

公开(公告)日：2025-03-13

申请号：US18896256

申请日：2024-09-25

Applicant: Life Technologies Corporation

Inventor： Rajesh Gottimukkala ,  Amir Marcovitz ,  Jeoffrey Schageman ,  Varun Bagai ,  Jian Gu ,  James Veitch ,  Kelli Bramlett ,  Scott Myrand ,  Fiona Hyland ,  Seth Sadis ,  Paul Williams

IPC: C12Q1/6851 ,  G06F17/18 ,  G16B25/10

Abstract: A method for detecting a gene fusion includes amplifying a nucleic acid sample in the presence of primer pool to produce a plurality of amplicons. The primer pool includes primers targeting a plurality of exon-exon junctions of a driver gene. The amplicons correspond to the exon-exon junctions. The amplicons are sequenced and aligned to a reference sequence. The number of reads corresponding to each amplicon is normalized to give a normalized read count. A baseline correction is applied to the normalized read counts for the amplicons to form corrected read counts. A binary segmentation score is calculated for each corrected read count. A predicted breakpoint for the gene fusion is determined based on the amplicon index corresponding to the maximum absolute binary segmentation score. Gene fusion events may be detected in a partner agnostic manner, i.e. without prior knowledge of the specific fusion partner genes or specific breakpoint information.

公开(公告)号：US20140357573A1

公开(公告)日：2014-12-04

申请号：US14210124

申请日：2014-03-13

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Seth SADIS ,  Paul Williams

IPC: C12Q1/68

Abstract: Methods for predicting clinical outcome for a human subject diagnosed with squamous cell lung carcinoma using a panel of molecular markers that includes CDKN2A and CCND1. The markers are related to the subject's increased likelihood of a negative clinical outcome.

Abstract translation: 使用包括CDKN2A和CCND1在内的一组分子标记物预测诊断为鳞状细胞肺癌的人类受试者的临床结果的方法。 标记与受试者增加阴性临床结果的可能性有关。